Compare CNM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNM | UTHR |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 20.3B |
| IPO Year | 2021 | 1999 |
| Metric | CNM | UTHR |
|---|---|---|
| Price | $50.26 | $488.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $60.00 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.5M | 424.3K |
| Earning Date | 12-09-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.24 | ★ 16.08 |
| EPS | 2.25 | ★ 26.38 |
| Revenue | ★ $7,740,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | $4.45 | $13.64 |
| Revenue Next Year | $4.43 | $5.78 |
| P/E Ratio | $22.35 | ★ $18.55 |
| Revenue Growth | 11.02 | ★ 13.50 |
| 52 Week Low | $43.18 | $266.98 |
| 52 Week High | $67.18 | $492.62 |
| Indicator | CNM | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 68.10 |
| Support Level | $44.59 | $470.13 |
| Resistance Level | $50.10 | $492.62 |
| Average True Range (ATR) | 1.61 | 10.72 |
| MACD | 0.65 | -0.53 |
| Stochastic Oscillator | 93.62 | 89.55 |
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.